Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
March 05, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir’s lead product candidate focused on reversing age-related decline and the extension of human life ...
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
February 13, 2024 16:05 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
February 08, 2024 17:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing...